Home › Trial NCT07848633
HER2-positive Breast Cancer Without Intravenous Neoadjuvant Therapy
- Trial IDNCT07848633
- StatusNot Yet Recruiting
- PhasePhase 2
- Study typeInterventional
- SponsorThe First Affiliated Hospital with Nanjing Medical University
- Enrollment65
- Start date2026-10-01
- ConditionsHER 2 Positive Advanced Breast Cancer
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.